Trade Names:
Synonyms:
Status: Approved (2012)
Entry Type: Small molecule
Molecule Category: Parent
ATC: J05AJ02
UNII: 4GDQ854U53

Structure

InChI Key JUZYLCPPVHEVSV-LJQANCHMSA-N
Smile COc1cc2c(cc1Cc1cccc(Cl)c1F)c(=O)c(C(=O)O)cn2[C@H](CO)C(C)C
InChI
InChI=1S/C23H23ClFNO5/c1-12(2)19(11-27)26-10-16(23(29)30)22(28)15-8-14(20(31-3)9-18(15)26)7-13-5-4-6-17(24)21(13)25/h4-6,8-10,12,19,27H,7,11H2,1-3H3,(H,29,30)/t19-/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C23H23ClFNO5
Molecular Weight 447.89
AlogP 4.28
Hydrogen Bond Acceptor 5.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 7.0
Polar Surface Area 88.76
Molecular species ACID
Aromatic Rings 3.0
Heavy Atoms 31.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Human immunodeficiency virus type 1 integrase inhibitor DailyMed
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Hydrolase
- 2-8100 - - 94-98

Indications

Mesh Heading Maximum Phase Mesh ID Reference
HIV Infections 4 D015658 ClinicalTrials
Acquired Immunodeficiency Syndrome 3 D000163 ClinicalTrials
Insulin Resistance 1 D007333 ClinicalTrials

Related Entries

Scaffolds

Mixture
Mixture

Side Effects from Label

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
Congenital, familial and genetic disorders
21.05
Pregnancy, puerperium and perinatal conditions
18.42
Injury, poisoning and procedural complications
15.79
Musculoskeletal and connective tissue disorders
10.53
Infections and infestations
5.26
Investigations
5.26
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
5.26
Renal and urinary disorders
5.26
Cardiac disorders
2.63
Gastrointestinal disorders
2.63
General disorders and administration site conditions
2.63
Nervous system disorders
2.63
Vascular disorders
2.63

Cross References

Resources Reference
CAS NUMBER 697761-98-1
ChEBI 72289
ChEMBL CHEMBL204656
DrugBank DB09101
DrugCentral 4300
FDA SRS 4GDQ854U53
PDB ELV
PubChem 5277135
SureChEMBL SCHEMBL726252
ZINC ZINC000013682481